Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for February 2008.

Pharmaceutical Technology


Agreements

DSM Signs Supply Agreement with IEP

DSM Pharma Chemicals (Parsippany, NJ), a business unit of DSM Pharmaceutical Products, entered into an enzyme- supply agreement with IEP (Wiesbaden, Germany) to enable fast and secure scale-up of chiral alcohol manufacturing. Under the terms of the agreement, DSM Pharma Chemicals has access to IEP's alcohol dehydrogenases, as well as a supply of IEP enzymes at commercial scale. DSM can source the enzymes from IEP or produce them in its own manufacturing facilities in Delft, The Netherlands, Capua, Italy, and Seclin, France. According to Oliver May, DSM's competence manager for biocatalysis, a flexible enzyme supply chain is key to the timely delivery of products to DSM's customers.

Akrimax Purchases Wyeth Plant

Akrimax Pharmaceuticals (Cranford, NJ) acquired Wyeth's (Madison, NJ) drug-product manufacturing and packaging plant in Rouses Point, New York. The acquisition prevents the plant's closure. Wyeth had planned to phase out its operations at the Rouses Point plant because of changes in product demand and a reassessment of its manufacturing network.

Akrimax is an emerging branded-pharmaceutical company led by a management team with expertise in the development, manufacturing, distribution, marketing, and sales of pharmaceutical products.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here